No description yet.
New York, NY
1 source · checked 1 time, last 1h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The SEC filing reports an exempt offering but does not state a round label, amount, valuation, or investors.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Form D (equity) [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | n/a | 2026-09-16 | not stated | No recent discussion |
1 source · checked 1 time, last 1h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The SEC filing reports an exempt offering but does not state a round label, amount, valuation, or investors. [ BUILT WITH ]·[ SEARCH ]from a Form D filing·[ SCRAPE ]1 page read: sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | $25 million | 2026-03-23 | RTW Investments | |
| Equity | $31,120,000 | 2025-11-25 | not stated | |
Amani Therapeutics develops safer, more effective psychiatric medicines for people living with serious neuropsychiatric disorders, starting with AM-01, a fixed-dose combination intended to preserve clozapine's efficacy while reducing its safety and monitoring burden.
Checked against 11 sources today
None named.
Also named as backers in company research: RTW Investments